Fusion Antibodies PLC Total Liabilities
Fusion Antibodies PLC total liabilities. Based on the latest financial reports, Fusion Antibodies PLC (FAB) has total liabilities worth GBX1.09 Million GBX (≈ $132.13 USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of Fusion Antibodies PLC to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Fusion Antibodies PLC (2006–2025)
Total liabilities of Fusion Antibodies PLC from 2006 to 2025. This chart illustrates how Fusion Antibodies PLC's total liabilities have evolved over time, based on quarterly financial data.
Fusion Antibodies PLC Competitors by Total Liabilities
The table below lists competitors of Fusion Antibodies PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Transense Technologies PLC
LSE:TRT
|
UK | GBX1.24 Million |
|
abrdn Property Income Trust Ltd.
LSE:API
|
UK | GBX752.86K |
|
Tower Resources plc
LSE:TRP
|
UK | GBX4.26 Million |
|
Itim Group PLC
LSE:ITIM
|
UK | GBX8.19 Million |
|
Goldstone Resources Ltd
LSE:GRL
|
UK | GBX17.15 Million |
|
Landore Resources Plc
LSE:LND
|
UK | GBX197.69K |
|
Lion Group Holding Ltd
NASDAQ:LGHL
|
USA | $32.32 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Fusion Antibodies PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Fusion Antibodies PLC.
Liquidity & Leverage Metrics
Fusion Antibodies PLC Total Liabilities Ratios Explained
Fusion Antibodies PLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fusion Antibodies PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fusion Antibodies PLC (2006–2025)
The table below shows the annual total liabilities of Fusion Antibodies PLC from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | GBX654.00K ≈ $79.57 |
+4.31% |
| 2024-03-31 | GBX627.00K ≈ $76.29 |
-33.23% |
| 2023-03-31 | GBX939.00K ≈ $114.25 |
-23.72% |
| 2022-03-31 | GBX1.23 Million ≈ $149.78 |
+13.67% |
| 2021-03-31 | GBX1.08 Million ≈ $131.77 |
-11.81% |
| 2020-03-31 | GBX1.23 Million ≈ $149.41 |
+38.21% |
| 2019-03-31 | GBX888.53K ≈ $108.11 |
+40.24% |
| 2018-03-31 | GBX633.59K ≈ $77.09 |
+40.73% |
| 2017-03-31 | GBX450.22K ≈ $54.78 |
+9.43% |
| 2016-03-31 | GBX411.43K ≈ $50.06 |
+104.01% |
| 2015-03-31 | GBX201.67K ≈ $24.54 |
-32.23% |
| 2014-03-31 | GBX297.57K ≈ $36.21 |
+17.35% |
| 2013-03-31 | GBX253.56K ≈ $30.85 |
-42.76% |
| 2012-03-31 | GBX443.00K ≈ $53.90 |
+15.97% |
| 2011-03-31 | GBX382.00K ≈ $46.48 |
+25.25% |
| 2010-03-31 | GBX305.00K ≈ $37.11 |
-51.82% |
| 2009-03-31 | GBX633.00K ≈ $77.02 |
+37.01% |
| 2008-03-31 | GBX462.00K ≈ $56.21 |
+3.36% |
| 2007-03-31 | GBX447.00K ≈ $54.39 |
+54.14% |
| 2006-03-31 | GBX290.00K ≈ $35.28 |
-- |
About Fusion Antibodies PLC
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and … Read more